Patent cliff sends Big Pharma shopping in China's record deal market — long diversified drug majors

Verdict: A real thesis with real cracks — watch, don't buy yet

The thesis has genuine support: AZN grew FY2025 revenue 8.6% to $58.7B with free cash flow of $11.8B in the top 1% of Health Care, and NVS produced $17.6B of free cash flow while shrinking shares 3.4% and lifting its dividend 19.5% to $4.77 per share — balance sheets clearly capable of funding the China-licensing wave the idea describes. The strongest point against is the split quality inside the basket: PFE's Q2 2026 free cash flow collapsed 86.1% quarter over quarter to just $302M with debt-to-equity rising to 0.74, and MRK posted back-to-back net losses while provisional September 30, 2026 ownership filings show net insider selling of roughly $28.6M. Nothing is actionable today — the entry rules have never fired across 1,232 evaluated daily bars, so this is a watch-list waiting for a close through the 50-day EMA with RSI (14) still under 45, and PFE sits closest at just $0.55 above its $27.25 trigger. The verdict flips if the next monthly ownership filing (a final, not provisional, read) confirms insider buying across the basket or a major China-licensing deal is announced by one of these four names.

Trade now

Nothing is actionable today: this is a watch-list setup, and none of the four entry rules has fired. The last daily close puts AZN at $156.90, MRK at $144.30, NVS at $141.00, and PFE at $27.80. On the momentum leg, all four already qualify — RSI (14) sits at 28.2 for AZN, 42.4 for MRK, 38.1 for NVS, and 37.7 for PFE, all below the 45 threshold. What is missing is the price-versus-trend leg: the rules want the close above the 50-day EMA (currently about $165.65 for AZN, $137.36 for MRK, $148.00 for NVS, and $27.25 for PFE) at the same moment MACD (12,26,9) crosses above its signal line. AZN would need to recover roughly $8.75 to clear its EMA, MRK about $6.94, NVS about $7.00, and PFE just $0.55 — PFE is the one sitting essentially on its trigger line. When a position does open, the mechanics are fixed: sizing is capped at 25% of the book per name, risk per position is set at 2.4%, a stop closes the trade at a 2.4% loss, and a take-profit closes it at a 4.7% gain — roughly two dollars of target for every dollar of risk. Level-based exits frame the same picture: each name also exits if it closes back below its 100-day SMA, at resistance for profit, or at the second-ranked support for loss. For AZN that means the 100-day SMA at about $172.62, first resistance at $160, and the next support level below the $156.74 floor as the soft downside marker. So "wait" means concretely: hold no positions, check each day's close against the four EMA levels above, and act only when a close crosses the EMA with RSI (14) still under 45 and a same-day MACD crossover. One transparency note matters to the plan: because the compiled entry conditions never produced an entry across the evaluated history, the research author authorized a bounded expanded search of the trigger thresholds — same thesis, symbols, direction, exits, and risk — so the exact trigger prices above may tighten before anything goes live. No nearby-parameter recommendation was established, so trade the levels as published, not an optimized variant.

Growth refill the thesis needs: cash-rich majors with elite free cash flow

The idea argues that patent-cliff pressure is pushing Western drugmakers to license Chinese innovation, and that diversified majors are the cleanest way to own that deal flow. The fundamentals back the premise that these companies have both the cash to pay for it and a growth gap to fill. AZN's FY2025 revenue rose 8.6% year over year to $58.7B, with net income up 45.3% to $10.2B and free cash flow up 18.4% to $11.8B — free cash flow sitting in the top 1% of the Health Care sector. NVS produced $17.6B of free cash flow in FY2025, up 8.3% and also a top-1% peer figure, while returning capital: shares outstanding fell 3.4% year over year and the dividend was raised 19.5% to $4.77 per share. These are balance sheets that can fund the multibillion-dollar China licensing deals described in the CNBC piece from October 2 without strain. The pipeline-gap framing is visible in the numbers too. MRK's Q4 2025 gross margin of 66.2% was well below its FY2024 level of 76.3%, and the company posted a Q1 2026 net loss of $4.2B before narrowing it to a $1.3B loss in Q2 2026 — evidence that growth and margin pressure is real and that deal-driven replenishment matters. PFE is under similar strain, with Q2 2026 free cash flow collapsing 86.1% quarter over quarter to just $302M and revenue growth at the 33rd percentile of the sector. The thesis is exactly the kind of response these fundamentals call for. For investors wanting exposure without single-deal risk, the basket structure helps. AZN operates at a 92nd-percentile operating margin (23.4%) with an 81.9% gross margin and a 21% return on equity, up 3.8 points year over year; NVS runs a 30.3% ROE at the 87th percentile. Each major also pays a well-covered dividend — PFE's trailing payout of $1.72 per share has been steady since 2021 — so a long basket collects income while the China-licensing catalysts play out. Per the Bloomberg report on October 4, record Hong Kong fundraising makes financing this deal wave easier still. One process note on timing: the entry rules were evaluated on real daily bars but did not open an entry in the last 60 months (1,232 evaluated bars, zero trades across the 60-, 24-, and 12-month windows), so this is a watch-list setup awaiting the momentum-turn condition rather than an active signal.

The bull case runs through PFE and MRK's deteriorating quarters — and the signal hasn't fired in five years

The weakest links in this basket are doing a lot of damage to the growth-refill narrative. MRK posted a $4.2B net loss in Q1 2026, followed by another $1.3B loss in Q2 2026, with return on equity still negative at -3.2%. Worse for the ownership case, insider activity at MRK was net open-market selling of roughly $28.6M as of the provisional filings for the period ended September 30, 2026 — and because those filings are provisional, that reading could still change when final disclosure arrives. AZN also showed net insider selling of about $2.2M on the same provisional basis. Leadership churn adds friction: PFE has…

Scores

• Conviction score breakdown: 53
• Thesis support: 68
• Trade readiness: 35
• Risk quality: 55
• Trigger proximity: 45
• Fundamentals trend: 62

Watch items

• AZN — Close vs 50-day EMA
• MRK — Close vs 50-day EMA
• NVS — Close vs 50-day EMA
• PFE — Close vs 50-day EMA
• AZN — Close vs rank-2 support
• PFE — Insider net open-market activity
• MRK — Insider net open-market activity
• PFE — Quarterly free cash flow
• MRK — Next dividend ex-date